Wells Fargo analyst Stephen Baxter raised the firm’s price target on McKesson (MCK) to $772 from $766 and keeps an Equal Weight rating on the shares. The firm is updating model following solid Q1 2026 earnings. Beyond the Norway divestiture accounting impact, Wells’ estimates for Medical and U.S. Pharma are modestly higher.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson’s Strong Long-Term Growth Potential Justifies Buy Rating Despite Limited Immediate Upside
- McKesson’s Earnings Call Highlights Strong Growth and Strategic Moves
- McKesson price target raised to $830 from $824 at TD Cowen
- McKesson Corporation Reports Strong Q1 2026 Results
- McKesson’s Strong Performance and Strategic Moves Earn a Buy Rating from Charles Rhyee